Olmesartan strong for Daiichi Sankyo as it builds up vaccines activities
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has reported a generally strong first quarter, in which global sales of its top product, the antihypertensive olmesartan, rose by 8% to ¥60.2 billion ($689.6 million; including in combinations).